Optimisation of treatment in patients with CRSwNP. An RCT of mepolizumab and surgical treatment with FESS and mepolizumab versus only mepolizumab over a 6- and 12-month follow-up

Status

Not yet recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-514632-24-02

Enrollment

Registered

2024-08-30

Start date

Unknown

Completion date

Unknown

Last updated

2025-09-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Rhinosinusitis with Nasal Polyposis

Brief summary

Change in SNOT-22 score, Nasal polyp score and smell

Interventions

DRUGMEPOLIZUMAB

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change in SNOT-22 score, Nasal polyp score and smell	—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026